Gyroscope complements dry AMD

Gyroscope's one-shot dry AMD therapy supplies an upstream complement factor

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators.

On Feb. 19, Gyroscope began Phase I/II testing of GT005, an undisclosed complement gene encoded in an adeno-associated viral (AAV) vector and administered via subretinal injection, for dry AMD. Syncona Ltd. launched Gyroscope

Read the full 642 word article

How to gain access

Continue reading with a
two-week free trial.